In 2003, scientists at London’s Imperial College hatched a somewhat out-there idea. They wanted to deal with the increasingly pesticide-resistant mosquitoes that were killing half a million people a year by spreading malaria in sub-Saharan Africa. What biologists Austin Burt and Andrea Crisanti proposed was nothing short of hacking the laws of heredity.

By planting a deadly gene in mosquito DNA, and engineering it such that the modification would spread through each generation faster than nature intended, they figured they could completely crash a population with just a few Trojan skeeters. This concept of a “gene drive” was decades-old, but no one had successfully concocted one in a lab, let alone applied it to a global public health scourge.

Fifteen years and $100 million dollars later, the scientists from Imperial College have finally succeeded, at least on the first count. Using Crispr, Burt and Crisanti’s team wiped out caged cohorts of the malaria-touting mosquito Anopheles gambiae in as few as seven generations. The results, published today in Nature Biotechnology, represent the first-ever annihilation of a population of animals via gene drive.

“It’s a really stunning development,” says Omar Akbari, an entomologist at UC San Diego1 who was not connected to the study. Akbari’s lab works on gene drives to make mosquitoes resistant to malaria, largely because an eradication approach was long believed to be impossible. “There’s just a huge evolutionary pressure on the organism to resist.”

But by exploiting a critical gene without any flexibility for spontaneously mutating its way around the drive, the London team overcame the persistent resistance problem.

“This is the first time we’ve shown that we can, in principle, manipulate the fate of an entire species,” says Crisanti, whose groundbreaking work has been supported in large part by the Bill and Melinda Gates Foundation, the world’s leading funder of gene drive technologies. Beginning in 2011, the researchers formally teamed up with partner institutions in Burkina Faso, Uganda, and Mali to establish local insectaries and field sites to one day test a malaria-eradicating gene drive in the wild. If all goes well, the Gates-backed project, called Target Malaria, could be applying for a permit to field-test Imperial College’s Crispr’d mosquitoes as early as 2024.

More tests have to be done first. While the gene drive worked well in small, 20-cubic centimeter cages with a laboratory strain of Anopheles gambiae, that’s no guarantee it will work in the jungles and savannas of Africa. To understand how the modified mosquitoes will behave in a more realistic environment, the next stage is to test them in larger contained areas, as tall as a person and up to fifteen feet long. This environment (still a far cry from the boundless natural world) can be tuned to mimic the circadian rhythms and atmospheric conditions of the outdoor test sites in Africa they will use in the future. The mosquitoes are expected to take on more natural behaviors, like swarming to find a mate, that were absent in the small cages.

In June, Crisanti’s lab sent a secure box filled with tiny, dark, cucumber-shaped mosquito eggs to a custom-built facility outside of Rome, where this next round of testing is already taking place. There, researchers are beginning to cross the gene drive-loaded lab strain with wild Anopheles gambiae shipped in from test sites in Burkina Faso. Then they’ll study how the modification spreads through these more genetically diverse local strains. And they’ll keep track of how successful those mosquitoes are at finding mates. In order to spread their genetic time bomb through a wild population, they have to be competitive with wild males. All of this data will be collected to submit to regulators whenever Target Malaria is confident they have a product that works.

‘At some point the science will be ready,” says Target Malaria engagement manager Delphine Thizy. “Then it will be a matter of public acceptance and regulatory frameworks that will need to catch up.”